Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Dolutegravir/phenobarbital interaction

Dolutegravir/phenobarbital interaction Reactions 1704, p143 - 2 Jun 2018 Decreased dolutegravir concentration: case report A 41-year-old man showed decreased plasma concentration of dolutegravir following concomitant administration of dolutegravir and phenobarbital [routes not stated]. The man, who had HIV infection, started receiving combination antiretroviral treatment (cART) with dolutegravir 50mg daily with concomitant tenofovir disoproxil fumarate/ emtricitabine. He had been taking phenobarbital 40mg daily as hypnotic along with various other drugs. The dolutegravir and phenobarbital were administered at bedtime at more than 3 4 hours after dinner. He complained of nocturnal awakening. Therefore, flunitrazepam was replaced with nitrazepam at cART day 140. On day 168 of the start of cART, due to insufficient sleep, nitrazepam was discontinued and the dose of phenobarbital was increased 70mg daily along with chlorpromazine and promethazine. His sleep disturbance continued and a potential drug-drug interaction between dolutegravir and phenobarbital was considered. Therefore, the man’s dose of chlorpromazine, promethazine and phenobarbital were reduced to 25mg, 12.5mg and 40mg daily. On day 196 of the start of cART, suvorexant was added to the treatment. On day 224 of the start of cART, the doses of chlorpromazine and phenobarbital were further reduced to 12.5mg and 30mg daily, respectively to improve the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Dolutegravir/phenobarbital interaction

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Dolutegravir/phenobarbital interaction

Abstract

Reactions 1704, p143 - 2 Jun 2018 Decreased dolutegravir concentration: case report A 41-year-old man showed decreased plasma concentration of dolutegravir following concomitant administration of dolutegravir and phenobarbital [routes not stated]. The man, who had HIV infection, started receiving combination antiretroviral treatment (cART) with dolutegravir 50mg daily with concomitant tenofovir disoproxil fumarate/ emtricitabine. He had been taking phenobarbital 40mg daily as hypnotic along...
Loading next page...
 
/lp/springer_journal/dolutegravir-phenobarbital-interaction-ywIePIcWuG

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46786-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p143 - 2 Jun 2018 Decreased dolutegravir concentration: case report A 41-year-old man showed decreased plasma concentration of dolutegravir following concomitant administration of dolutegravir and phenobarbital [routes not stated]. The man, who had HIV infection, started receiving combination antiretroviral treatment (cART) with dolutegravir 50mg daily with concomitant tenofovir disoproxil fumarate/ emtricitabine. He had been taking phenobarbital 40mg daily as hypnotic along with various other drugs. The dolutegravir and phenobarbital were administered at bedtime at more than 3 4 hours after dinner. He complained of nocturnal awakening. Therefore, flunitrazepam was replaced with nitrazepam at cART day 140. On day 168 of the start of cART, due to insufficient sleep, nitrazepam was discontinued and the dose of phenobarbital was increased 70mg daily along with chlorpromazine and promethazine. His sleep disturbance continued and a potential drug-drug interaction between dolutegravir and phenobarbital was considered. Therefore, the man’s dose of chlorpromazine, promethazine and phenobarbital were reduced to 25mg, 12.5mg and 40mg daily. On day 196 of the start of cART, suvorexant was added to the treatment. On day 224 of the start of cART, the doses of chlorpromazine and phenobarbital were further reduced to 12.5mg and 30mg daily, respectively to improve the

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.